Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin...

NEJM's profile picture

NEJM

1,018,874 subscribers

32,419 Aufrufe • vor 8 Monaten •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:
1:06

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,312 Aufrufe • vor 3 Monaten

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib
1:28

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib

NEJM

15,621 Aufrufe • vor 4 Monaten

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:
0:58

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:

NEJM

12,257 Aufrufe • vor 4 Monaten

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:
1:28

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:

NEJM

16,994 Aufrufe • vor 14 Tagen

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.
1:12

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

Davide Capodanno

28,503 Aufrufe • vor 2 Jahren

Catheter-Directed PE Treatment: Does it Deliver? NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains a trial recently published in NEJM that compared catheter-directed thrombolysis to anticoagulation alone for acute, intermediate-risk pulmonary embolism. Read the key results and comment from Michael E. Billington, MD: Visit to see What Matters Most This Week, including: 🫀 New ACC/AHA Guideline on Lipid Management and ASCVD Prevention 💊 Chronic Beta-Blocker Use in Low-Risk Patients after MI: Time to Re-Evaluate 🧠 Reducing the Risk of Recurrent Stroke in Patients with Left Ventricular Dysfunction 🎯 What's the Ideal LDL Target for Patients with Cardiovascular Disease?
1:07

Catheter-Directed PE Treatment: Does it Deliver? NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains a trial recently published in NEJM that compared catheter-directed thrombolysis to anticoagulation alone for acute, intermediate-risk pulmonary embolism. Read the key results and comment from Michael E. Billington, MD: Visit to see What Matters Most This Week, including: 🫀 New ACC/AHA Guideline on Lipid Management and ASCVD Prevention 💊 Chronic Beta-Blocker Use in Low-Risk Patients after MI: Time to Re-Evaluate 🧠 Reducing the Risk of Recurrent Stroke in Patients with Left Ventricular Dysfunction 🎯 What's the Ideal LDL Target for Patients with Cardiovascular Disease?

NEJM

12,682 Aufrufe • vor 4 Monaten

"Taking An Aspirin Everyday To Prevent A Heart Attack Is Wrong, Dangerous & Can Be Deadly." Dr Jack Wolfson, Cardiologist "A Daily Aspirin Is A Lie That's Been Fed To Us For Over 50 Years." "Aspirin Does Not Protect You Or Fix Your Damaged Arteries...It Just Makes You Bleed." Almost 30 million Americans take aspirin for primary or secondary prevention of cardiovascular disease (CVD) or colorectal cancer (CRC). For decades, low dose Aspirin has been prescribed to patients as primary prevention for patients at risk for CVD, but has now been withdrawn as a line of treatment or prevention. The most recent recommendations from the US Preventive Services Task Force (USPSTF) have abandoned the routine call for daily aspirin use because of the harms that daily low dose aspirin causes. Research From The ARRIVE, ASPREE & ASCEND Peer Reviewed Studies, Confirms That Daily Aspirin, Even Low Dose 'Baby Aspirin,' Is Harmful & Causes Major Bleeding: More than 46,000 adults were studied for multiple years on low dose enteric coated 100 mg aspirin & found significant major bleeding while also finding no benefit for cardiovascular disease. The causal factor of the increased risk of bleeding is aspirin inhibits platelet activity as a COX-1 inhibitor, which damages the protective layer of gastrointestinal mucosa, intracranial brain tissue & micro bleeding anemia. 1⃣ Increased risk of major bleeding: This includes gastrointestinal (GI) bleeding (e.g., ulcers, bleeding in the stomach or intestines) & intracranial hemorrhage (bleeding in the brain), which can be severe & life-threatening. 2⃣ Hemorrhagic stroke: Aspirin increases the risk of hemorrhagic strokes, where a blood vessel bursts in the brain. Bleeding events were 38% higher among participants who were taking aspirin daily, regardless of their gender, age, or cardiovascular risk. 3⃣ Anemia: The ASPREE trial, showed 20% increase in Anemia, characterized by low red blood cell counts & symptoms like fatigue & weakness. Slow micro bleeding anemia as low Hemoglobin iron & Ferritin levels plummeting to less than 45 mcg/L. 4⃣ Gastrointestinal damage: Aspirin, even at low doses, causes damage to the lining of the stomach & intestines, leading to erosions, ulcers & bleeding. Research participant data showed 60% had major GI bleeds as a result of a daily low dose aspirin. 👇ASCEND Aspirin Bleeding Risk Study👇 👇Daily Low Dose Aspirin Causes Anemia👇 👇ASPREE Low Dose Aspirin Causes GI Bleeding👇 Speaker: Dr Jack Wolfson, MD
2:09

"Taking An Aspirin Everyday To Prevent A Heart Attack Is Wrong, Dangerous & Can Be Deadly." Dr Jack Wolfson, Cardiologist "A Daily Aspirin Is A Lie That's Been Fed To Us For Over 50 Years." "Aspirin Does Not Protect You Or Fix Your Damaged Arteries...It Just Makes You Bleed." Almost 30 million Americans take aspirin for primary or secondary prevention of cardiovascular disease (CVD) or colorectal cancer (CRC). For decades, low dose Aspirin has been prescribed to patients as primary prevention for patients at risk for CVD, but has now been withdrawn as a line of treatment or prevention. The most recent recommendations from the US Preventive Services Task Force (USPSTF) have abandoned the routine call for daily aspirin use because of the harms that daily low dose aspirin causes. Research From The ARRIVE, ASPREE & ASCEND Peer Reviewed Studies, Confirms That Daily Aspirin, Even Low Dose 'Baby Aspirin,' Is Harmful & Causes Major Bleeding: More than 46,000 adults were studied for multiple years on low dose enteric coated 100 mg aspirin & found significant major bleeding while also finding no benefit for cardiovascular disease. The causal factor of the increased risk of bleeding is aspirin inhibits platelet activity as a COX-1 inhibitor, which damages the protective layer of gastrointestinal mucosa, intracranial brain tissue & micro bleeding anemia. 1⃣ Increased risk of major bleeding: This includes gastrointestinal (GI) bleeding (e.g., ulcers, bleeding in the stomach or intestines) & intracranial hemorrhage (bleeding in the brain), which can be severe & life-threatening. 2⃣ Hemorrhagic stroke: Aspirin increases the risk of hemorrhagic strokes, where a blood vessel bursts in the brain. Bleeding events were 38% higher among participants who were taking aspirin daily, regardless of their gender, age, or cardiovascular risk. 3⃣ Anemia: The ASPREE trial, showed 20% increase in Anemia, characterized by low red blood cell counts & symptoms like fatigue & weakness. Slow micro bleeding anemia as low Hemoglobin iron & Ferritin levels plummeting to less than 45 mcg/L. 4⃣ Gastrointestinal damage: Aspirin, even at low doses, causes damage to the lining of the stomach & intestines, leading to erosions, ulcers & bleeding. Research participant data showed 60% had major GI bleeds as a result of a daily low dose aspirin. 👇ASCEND Aspirin Bleeding Risk Study👇 👇Daily Low Dose Aspirin Causes Anemia👇 👇ASPREE Low Dose Aspirin Causes GI Bleeding👇 Speaker: Dr Jack Wolfson, MD

Valerie Anne Smith

209,973 Aufrufe • vor 11 Monaten

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:
1:18

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

47,843 Aufrufe • vor 7 Monaten

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:
1:29

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:

NEJM

13,328 Aufrufe • vor 6 Monaten

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full trial results and Research Summary:
1:04

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full trial results and Research Summary:

NEJM

25,324 Aufrufe • vor 6 Monaten

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR
1:46

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR

PCRonline 🫀

31,019 Aufrufe • vor 3 Jahren

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:
1:20

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:

NEJM

18,745 Aufrufe • vor 6 Monaten

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:
1:27

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

NEJM

89,790 Aufrufe • vor 6 Monaten

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:
1:20

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:

NEJM

16,263 Aufrufe • vor 9 Monaten

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:
1:46

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,797 Aufrufe • vor 1 Jahr

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:
1:14

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:

NEJM

12,637 Aufrufe • vor 1 Monat

Among patients with #diabetes but without known significant atherosclerosis, intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial. #ACC26 American College of Cardiology 🎥 Watch the video and read the full article:
1:23

Among patients with #diabetes but without known significant atherosclerosis, intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial. #ACC26 American College of Cardiology 🎥 Watch the video and read the full article:

JAMA

14,124 Aufrufe • vor 4 Monaten

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:
1:32

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:

NEJM

15,827 Aufrufe • vor 1 Monat

Peripheral artery disease is linked to cardiovascular risk and impaired mobility. Diagnosis relies on ankle–brachial index testing, and management involves cardiovascular risk reduction, exercise, and selective revascularization. Learn more in the Clinical Practice article “Peripheral Artery Disease in the Legs” by Mary M. McDermott, MD, from the Northwestern University Feinberg School of Medicine (Northwestern Feinberg School of Medicine):
1:21

Peripheral artery disease is linked to cardiovascular risk and impaired mobility. Diagnosis relies on ankle–brachial index testing, and management involves cardiovascular risk reduction, exercise, and selective revascularization. Learn more in the Clinical Practice article “Peripheral Artery Disease in the Legs” by Mary M. McDermott, MD, from the Northwestern University Feinberg School of Medicine (Northwestern Feinberg School of Medicine):

NEJM

13,053 Aufrufe • vor 6 Monaten

🟩TIMI TIMI (Thrombolysis in Myocardial Infarction) flow is an angiographic grading system used to describe the degree of epicardial coronary blood flow after reperfusion therapy (thrombolysis or PCI) in acute myocardial infarction. It was developed by the TIMI study group to provide a standardized, reproducible way to assess coronary perfusion on angiography. TIMI flow grades 🟥TIMI 0: No perfusion There is no antegrade flow beyond the point of coronary occlusion. 🟪TIMI 1: Penetration without perfusion Contrast passes beyond the obstruction but fails to opacify the entire distal coronary bed and appears to stagnate. 🟦TIMI 2: Partial perfusion Contrast crosses the obstruction and opacifies the distal bed, but flow and/or clearance is slower than in normal or non-affected coronary segments. 🟩TIMI 3: Complete perfusion Normal antegrade flow with rapid filling and clearance of contrast in the distal coronary bed, comparable to an uninvolved vessel. Key point TIMI flow reflects epicardial coronary artery patency, not microvascular perfusion. Achieving TIMI 3 flow is strongly associated with better clinical outcomes after myocardial infarction. CardiovascularCorner
0:53

🟩TIMI TIMI (Thrombolysis in Myocardial Infarction) flow is an angiographic grading system used to describe the degree of epicardial coronary blood flow after reperfusion therapy (thrombolysis or PCI) in acute myocardial infarction. It was developed by the TIMI study group to provide a standardized, reproducible way to assess coronary perfusion on angiography. TIMI flow grades 🟥TIMI 0: No perfusion There is no antegrade flow beyond the point of coronary occlusion. 🟪TIMI 1: Penetration without perfusion Contrast passes beyond the obstruction but fails to opacify the entire distal coronary bed and appears to stagnate. 🟦TIMI 2: Partial perfusion Contrast crosses the obstruction and opacifies the distal bed, but flow and/or clearance is slower than in normal or non-affected coronary segments. 🟩TIMI 3: Complete perfusion Normal antegrade flow with rapid filling and clearance of contrast in the distal coronary bed, comparable to an uninvolved vessel. Key point TIMI flow reflects epicardial coronary artery patency, not microvascular perfusion. Achieving TIMI 3 flow is strongly associated with better clinical outcomes after myocardial infarction. CardiovascularCorner

CardiovascularCorner

10,986 Aufrufe • vor 7 Monaten